Short- And Long-Term biologic variability of galectin-3 and other cardiac biomarkers in patients with stable heart failure and healthy adults

Clinical Chemistry

Volumn 62, Issue 2, 2016, Pages 360-366

  Schindler, Emily I ^a   Szymanski, Jeffrey J ^a   Hock, Karl G ^a   Geltman, Edward M ^b   Scott, Mitchell G ^a  

^a Department of Pathology and Immunology   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; TROPONIN I; BIOLOGICAL MARKER; GALECTIN-3, HUMAN;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART FAILURE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; BLOOD; MIDDLE AGED; REFERENCE VALUE;

ADULT; AGED; BIOMARKERS; FEMALE; GALECTIN 3; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; REFERENCE VALUES; TROPONIN I;

EID: 84957106843     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.246553     Document Type: Article

References (29)

1. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: A novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011; 12:200 -10.
2. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E, Morrow DA. Galectin-3 and the development of heart failure after acute coronary syndrome: Pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58:267-73.
3. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249 -56.
4. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, van Veldhuisen DJ. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43: 60-8.
5. Maiolino G, Rossitto G, Pedon L, Cesari M, Frigo AC, Azzolini M, et al. Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015;35: 725-32.
6. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am Heart J 2014;167:674 - 82 e1.
7. De Boer RA, van Veldhuisen DJ, deFilippii C, Muntendam P, Adourian AS, Guo Y, et al. Plasma galectin-3 is associated with near-term rehospitalization in heart failure: A meta-analysis. J Card Fail 2011;17:S93.
8. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491-500.
9. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409 -37.
10. Harris EK, Yasaka T. On the calculation of a "reference change" for comparing two consecutive measurements. Clin Chem 1983;29:25-30.
11. Ford BA, Coyne DW, Eby CS, Scott MG. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009;75: 104 -10.
12. Nordenskjold AM, Ahlstrom H, Eggers KM, Frobert O, Jaffe AS, Venge P, Lindahl B. Short- And long-term indi-vidual variation in cardiac troponin in patients with stable coronary artery disease. Clin Chem 2013;59: 401-9.
13. Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J 2013;165:995-9.
14. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574 - 81.
15. Fokkema MR, Herrmann Z, Muskiet FA, Moecks J. Reference change values for brain natriuretic peptides revisited. Clin Chem 2006;52:1602-3.
16. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55- 64.
17. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L, et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-Action study. Circ Heart Fail 2012;5:72- 8.
18. Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb 2012;19: 1073- 82.
19. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013;6:219 -26.
20. Frankenstein L, Wu AH, Hallermayer K, Wians FH Jr, Giannitsis E, Katus HA. Biological variation and reference change value of high-sensitivity troponin T in healthy individuals during short and intermediate follow-up periods. Clin Chem 2011;57:1068 -71.
21. Vasile VC, Saenger AK, Kroning JM, Klee GG, Jaffe AS. Biologic variation of a novel cardiac troponin I assay. Clin Chem 2011;57:1080 -1.
22. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:1086 -90.
23. Miller WL, Hartman KA, Grill DE, Burnett JC Jr., Jaffe AS. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 2009;55:78 - 84.
24. O'Hanlon R, O'Shea P, Ledwidge M, O'Loughlin C, Lange S, Conlon C, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007;13:50 -5.
25. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, Muskiet FA. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052- 8.
26. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM, et al. Biological variation for N-terminal proand B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;92:628 -31.
27. Apple FS, Collinson PO, Biomarkers ITFoCAoC. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54 - 61.
28. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012; 33:2252-7.
29. Wu AH, Lu QA, Todd J, Moecks J, Wians F. Short- And long-term biological variation in cardiac troponin I measured with a high-sensitivity assay: implications for clinical practice. Clin Chem 2009;55:52- 8.